Townsquare Capital LLC Has $20.07 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Townsquare Capital LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 12.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 123,812 shares of the company's stock after purchasing an additional 14,185 shares during the period. Townsquare Capital LLC's holdings in Johnson & Johnson were worth $20,065,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. International Assets Investment Management LLC lifted its stake in shares of Johnson & Johnson by 20,130.0% during the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company's stock valued at $559,832,000 after buying an additional 3,437,397 shares during the period. Marshall Wace LLP lifted its position in shares of Johnson & Johnson by 506.9% in the 2nd quarter. Marshall Wace LLP now owns 3,884,962 shares of the company's stock worth $567,826,000 after buying an additional 3,244,862 shares during the last quarter. Ninety One UK Ltd lifted its position in Johnson & Johnson by 59.0% in the 2nd quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company's stock valued at $980,579,000 after purchasing an additional 2,489,925 shares during the last quarter. Swedbank AB acquired a new position in Johnson & Johnson during the 1st quarter valued at about $331,178,000. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Johnson & Johnson by 10.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock worth $2,744,979,000 after purchasing an additional 1,831,751 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Royal Bank of Canada raised their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a report on Wednesday, October 16th. Guggenheim boosted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Wolfe Research began coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price on the stock. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $175.94.

Johnson & Johnson Stock Up 0.9 %

NYSE JNJ traded up $1.38 during trading hours on Wednesday, reaching $155.90. 1,795,870 shares of the company's stock were exchanged, compared to its average volume of 7,046,508. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $375.35 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53. The company's 50-day moving average is $159.73 and its two-hundred day moving average is $156.39. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.66 EPS. On average, analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson's payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.